Takeaways: Health Canada’s acceptance of Knight Therapeutics’ New Drug Submission for Gemtesa (vibegron) moves the therapy closer to potential approval in Canada for adults with overactive bladd...
Takeaways: The first Canadian use of Abbott’s Volt Pulsed Field Ablation (PFA) System at McGill University Health Centre marks the start of commercial adoption of a next‑generation AFib therapy ...
Minjuvi Gains Accelerated Funding in Ontario for Relapsed/Refractory Follicular Lymphoma Incyte announced that Minjuvi (tafasitamab), in combination with R² (lenalidomide and rituximab), is now funded...
Takeaways: Ontario’s FAST Program funding for Minjuvi (tafasitamab) plus R² gives eligible patients with relapsed or refractory follicular lymphoma earlier public access to a tar...
Takeaways: The pCPA Letter of Intent for Anzupgo (delgocitinib cream) moves Canada closer to public reimbursement for the first topical therapy specifically indicated for moderate to severe chro...
Takeaways: Siliq’s listing under Alberta’s public drug plan expands brodalumab’s public coverage across Canada, leaving only British Columbia without provincial reimbursement and improving...
Leqembi Receives Positive Public Reimbursement Recommendation in Canada BioArctic announced that CDA-AMC has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for el...
Takeaways: CDA-AMC’s conditional reimbursement recommendation for Yorvipath moves the therapy closer to public funding in Canada for adults with chronic hypoparathyroidism who are not ...
Takeaways: PixCell Medical’s Health Canada license and distribution partnership with Inter Medico give HemoScreen a direct route into Canada’s growing point-of-care diagnostics ma...
Takeaways: The positive reimbursement recommendation from Canada’s drug agency moves Leqembi closer to public funding for early Alzheimer’s disease, which can significantly expand the ...